Car-t cell therapy for treatment-resistant autoimmune nerve diseases
Part of Brain & nervous system, Cancer, Eyes & vision, Immune system & allergy clinical trials.
This early-stage trial uses a type of immune cell therapy (CAR-T cells) to treat severe autoimmune diseases that attack the nervous system, such as NMOSD, myasthenia gravis, CIDP, and multiple sclerosis. The goal is to see if this treatment can stop the immune system from damaging nerves when other treatments have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old (for multiple sclerosis, between 18 and 55).
- You have a refractory autoimmune disease of the nervous system, such as NMOSD, generalized myasthenia gravis, CIDP, or multiple sclerosis — and standard treatments haven't worked or aren't available.
- You can use reliable birth control (like condoms plus another method) during the study and for one year after treatment (if you or your partner can become pregnant).
- You have not had an organ transplant, active cancer in the past two years, or serious infections like hepatitis B, C, HIV, CMV, or syphilis.
- You do not have a primary immune deficiency, severe heart disease, or a history of psychiatric illness or drug abuse that hasn't been resolved.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This early-phase trial tests a new type of immune cell therapy (CAR-T) designed to target and calm the immune system in people with certain autoimmune neurological diseases that haven't improved with standard care. The goal is to see if it's safe and if it can reduce disease activity.
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
This study tests an experimental treatment called C-CAR168, which uses your own immune cells that have been modified to target and potentially slow down the progression of multiple sclerosis. It is for younger adults with progressive MS who have not responded well to standard treatments.
This trial tests a treatment called CNCT19, a type of CAR-T cell therapy, for people with certain autoimmune diseases like neuromyelitis optica, myasthenia gravis, or multiple sclerosis that have come back or not responded to other treatments. It aims to see if targeting a specific immune cell (CD19) can help control the disease.
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.